Daraxonrasib

Daraxonrasib (RMC-6236) is a RAS inhibitor drug. It is undergoing testing by Revolution Medicines to treat advanced solid tumors with RAS mutations, especially metastatic pancreatic ductal adenocarcinoma (PDAC) containing KRAS G12X mutations.^[1] It received a breakthrough therapy designation from the US FDA in 2025.^[2]

Pronunciation/dəˌræksɒnˈræsɪb/
də-RAK-son-RAS-ib

Other namesRMC-6236

CAS Number

• 2765081-21-6

PubChem CID

• 164726578

Quick facts Clinical data, Pronunciation ...

Daraxonrasib

Molecular structure of daraxonrasib
3D representation of a daraxonrasib molecule
Clinical data
Pronunciation	/dəˌræksɒnˈræsɪb/ də-RAK-son-RAS-ib
Other names	RMC-6236
Identifiers
IUPAC name (1S,2S)-N-[(12M,4S,63S)-11-ethyl-12-{2-[(1S)-1-methoxyethyl]-5-(4-methylpiperazin-1-yl)pyridin-3-yl}-10,10-dimethyl-5,7-dioxo-11H-8-oxa-1(5,3)-indola-6(1,3)-[1,2]diazinana-2(4,2)-[1,3]thiazolacycloundecaphan-4-yl]-2-methylcyclopropane-1-carboxamide
CAS Number	2765081-21-6
PubChem CID	164726578
IUPHAR/BPS	13368
ChemSpider	115275938
UNII	B6T47Y2UAP
KEGG	D13265
ChEBI	CHEBI:746946
Chemical and physical data
Formula	C44H58N8O5S
Molar mass	811.06 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCN1C2=C3C=C(C=C2)C4=CSC(=N4)C[C@@H](C(=O)N5CCC[C@H](N5)C(=O)OCC(CC3=C1C6=C(N=CC(=C6)N7CCN(CC7)C)[C@H](C)OC)(C)C)NC(=O)[C@H]8C[C@@H]8C
InChI InChI=1S/C44H58N8O5S/c1-8-51-37-12-11-28-19-31(37)33(40(51)32-20-29(23-45-39(32)27(3)56-7)50-16-14-49(6)15-17-50)22-44(4,5)25-57-43(55)34-10-9-13-52(48-34)42(54)35(21-38-46-36(28)24-58-38)47-41(53)30-18-26(30)2/h11-12,19-20,23-24,26-27,30,34-35,48H,8-10,13-18,21-22,25H2,1-7H3,(H,47,53)/t26-,27-,30-,34-,35-/m0/s1 Key:FVICRBSEYSHKFY-JYQNNKODSA-N

Close

Daraxonrasib is an orally active and multi-selective RAS inhibitor. It uses a tri-complex mechanism to target the active, GTP-bound form of RAS proteins, including mutant and wild-type forms. Unlike conventional RAS inhibitors, it first binds to the chaperone-like protein cyclophilin A to form a complex, which then attaches to active RAS. This interaction blocks downstream effector binding and inhibits oncogenic signaling.^[3]

In 2026, daraxonrasib completed a phase 3 clinical trial (RASolute 302) to assess efficacy compared to standard-of-care chemotherapy.^[4] The trial met all primary and key secondary endpoints, including progression-free survival (PFS). The company reported median survival of 13.2 months with daraxonrasib vs. 6.7 months with standard chemotherapy. The hazard ratio for death was 0.40 (a 60% reduction in risk of death; p < 0.0001). Daraxonrasib was generally well tolerated. Its side effects include rash, diarrhea, fatigue, nausea and raw, split fingertips.^[5] The safety profile is manageable with no new safety signals.^[6] Although the trial was randomized, it was open-label (not blinded), and both the patient and outcome assessors knew if a patient was administered Daraxonrasib.